Olympus Aktie
14,40EUR | -0,10EUR | -0,66% |
WKN: 856840 / ISIN: JP3201200007
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 89,11 |
Nomura Asset Management Co., Ltd. | 7,04 |
Baillie Gifford & Co. | 5,57 |
Capital Research & Management Co. (World Investors) | 5,23 |
Olympus Corp. | 4,24 |
American Funds EuroPacific Growth Fund | 3,52 |
Sumitomo Mitsui Banking Pension Fund | 3,35 |
Nomura Asset NEXT FUNDS NIKKEI 225 ETF (1321) | 3,01 |
Nomura Asset NEXT FUNDS TOPIX ETF (1306) | 2,83 |
Nippon Life Insurance Co. | 1,81 |
Mitsubishi UFJ Asset Management Co., Ltd. | 1,71 |
Dodge & Cox International Stock Fund | 1,68 |
Nikko Exchange Traded Index Fund 225 | 1,46 |
First Sentier Investors (Singapore) | 0,73 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 35 174 | 31 653 | 31 557 | 32 844 | 28 838 |
Umsatz pro Mitarbeiter in Mio. EUR | 22,67 | 23,08 | 27,53 | 26,85 | 32,46 |
Bilanz (in Mio. JPY) - Aktiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 506 707 | 580 162 | 694 605 | 726 357 | 800 340 |
Summe Anlagevermögen | 508 956 | 600 855 | 663 394 | 781 951 | 733 876 |
Summe Aktiva | 1 015 663 | 1 181 017 | 1 357 999 | 1 508 308 | 1 534 216 |
Bilanz (in Mio. JPY) - Passiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Fremdkapital | 643 705 | 785 537 | 846 637 | 867 074 | 777 030 |
Summe Eigenkapital | 371 958 | 395 480 | 511 362 | 641 234 | 757 186 |
Summe Passiva | 1 015 663 | 1 181 017 | 1 357 999 | 1 508 308 | 1 534 216 |
Adresse
Shinjuku Monolith, 163-0914 Tokyo | |
Telefon | +81 (3) 3340-2111 |
Fax | +81 (3) 3340-2062 |
Internet | http://www.olympus.co.jp |
Management
Akira Hasegawa
Executive Officer, Head-Research & Development |
André Roggan
Executive Officer & Chief Technology Officer |
Boris Shkolnik
Chief Quality Officer & Executive Officer |
David Robert Hale
Outside Director |
Eva Gardyan-Eisenlohr
Global Chief Compliance Officer |
Gabriela Kaynor
Chief Strategy Officer & Executive Officer |
Gary John Pruden
Independent Director |
Jimmy C. Beasley
Independent Outside Director |
John de Csepel
Chief Medical Officer |
Katsuyuki Saito
Executive Officer, Head-Corporate R&D |
Kohei Kan
Outside Director |
Luann M. Pendy
Outside Director |
Neil Boyden Tanner
Global General Counsel |
Sachiko Ichikawa
Outside Director |
Shigeto Ohtsuki
Executive Officer & Head-Human Resources |
Stephen Mark Kneebone
Chief Information Officer & Executive Officer |
Sumitaka Fujita
Independent Outside Director |
Takaaki Sakurai
Vice President-Investor Relations |
Takayuki Aoyagi
Vice President-Accounting |
Tatsuro Kosaka
Outside Director |
Tatsuya Izumi
Chief Financial Officer & Executive Officer |
Tetsuo Kobayashi
Chief Manufacturing & Supply Officer |
Tomohisa Sakurai
Executive Officer & Head-Therapeutic Solutions |
Toshihiko Okubo
Outside Director |
Wenlei Yang
Chief Diversity, Equity & Inclusion Officer |
Yasumasa Masuda
Independent Outside Director |
Yasuo Takeuchi
Executive Chairman & Chief Executive Officer |
Yasushi Shingai
Outside Director |
Yoshio Tashiro
Executive Officer & Head-Technology Strategy |